Seeing Is Believing
Currently out of the existing stock ratings of Joseph Munda, 14 are a BUY (77.78%), 4 are a HOLD (22.22%).
Analyst Joseph Munda, currently employed at FIRST ANALYSIS, carries an average stock price target met ratio of 90% that have a potential upside of 20.19% achieved within 540 days.
Joseph Munda’s has documented 40 price targets and ratings displayed on 5 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on NEO, NeoGenomics at 28-Feb-2020.
Analyst best performing recommendations are on ANIK (ANIKA THERAPEUTICS).
The best stock recommendation documented was for NEO (NEOGENOMICS) at 10/24/2018. The price target of $18 was fulfilled within 7 days with a profit of $3.59 (24.91%) receiving and performance score of 35.59.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
37
$11.3 (43.97%)
28
3 months 22 days ago
10/12 (83.33%)
$11.74 (46.48%)
110
Buy
32
$6.3 (24.51%)
61
1 years 22 days ago
1/3 (33.33%)
$11.99 (59.92%)
73
Hold
35
1 years 10 months 17 days ago
0/2 (0%)
$8.78 (33.49%)
Hold
46
$23.44 (103.90%)
46
2 years 9 months 13 days ago
0/2 (0%)
$5.44 (13.41%)
Buy
65
$39.3 (152.92%)
54
4 years 7 months 21 days ago
5/6 (83.33%)
$15.2 (30.52%)
21
What Year was the first public recommendation made by Joseph Munda?